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Abstract
Pompe disease is a lysosomal storage disease caused by the absence of acid -1,4 glucosidase 
(GAA). The pathophysiology of Pompe disease includes generalized myopathy of both 
cardiac and skeletal muscle. We sought to use recombinant adeno-associated virus (rAAV) 
vectors to deliver functional GAA genes in vitro and in vivo. Myotubes and fibroblasts from 
Pompe patients were transduced in vitro with rAAV2-GAA. At 14 days postinfection, GAA 
activities were at least fourfold higher than in their respective untransduced controls, with a 
10-fold increase observed in GAA-deficient myotubes. BALB/c and Gaa–/– mice were also 
treated with rAAV vectors. Persistent expression of vector-derived human GAA was 
observed in BALB/c mice up to 6 months after treat-ment. In Gaa–/– mice, intramuscular 
and intramyocardial delivery of rAAV2-Gaa (carrying the mouse Gaa cDNA) resulted in 
near-normal enzyme activities. Skeletal muscle contractility was partially restored in the 
soleus muscles of treated Gaa–/– mice, indicating the potential for vec-tor-mediated 
restoration of both enzymatic activity and muscle function. Furthermore, intra-muscular 
treatment with a recombinant AAV serotype 1 vector (rAAV1-Gaa) led to nearly eight times 
normal enzymatic activity in Gaa–/– mice, with concomitant glycogen clearance as assessed 
in vitro and by proton magnetic resonance spectroscopy.
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Pompe disease is a lysosomal storage disease caused by the absence of acid a.-1,4 glucosidase
(GAA). The pathophysiology of Pompe disease includes generalized myopathy of both cardiac 
and skeletal muscle. We sought to use recombinant adeno-associated virus (rAAV) vectors to 
deliver functional GAA genes in vitro and in vivo. Myotubes and fibroblasts from Pompe patients
were transduced in vitro with rAAV2-GAA. At 14 days postinfection, GAA activities were at least
fourfold higher than in their respective untransduced controls, with a 10-fold increase observed 
in GAA-deficient myotubes. BALB/c and Gaa–/– mice were also treated with rAAV vectors. Persistent
expression of vector-derived human GAA was observed in BALB/c mice up to 6 months after treat- 
ment. In Gaa–/– mice, intramuscular and intramyocardial delivery of rAAV2-Gaa (carrying the
mouse Gaa cDNA) resulted in near-normal enzyme activities. Skeletal muscle contractility was
partially restored in the soleus muscles of treated Gaa–/– mice, indicating the potential for vec- 
tor-mediated restoration of both enzymatic activity and muscle function. Furthermore, intra- 
muscular treatment with a recombinant AAV serotype 1 vector (rAAV1-Gaa) led to nearly eight
times normal enzymatic activity in Gaa–/– mice, with concomitant glycogen clearance as assessed
in vitro and by proton magnetic resonance spectroscopy.
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INTRODUCTION
Glycogen storage disease type II (GSDII; Pompe disease; 
MIM 232300) is an autosomal recessive disorder caused 
by a deficiency of the lysosomal enzyme acid a.-glucosidase 
(GAA; EC 3.2.1.20). GAA is responsible for the cleavage of 
a.-1,4 and a.-1,6 linkages in lysosomal glycogen, leading to 
the release of monosaccharides. A loss or absence of GAA 
activity leads to massive accumulation of lysosomal and 
cytoplasmic glycogen in striated muscle, causing contrac- 
tile apparatus disruption, and ultimately resulting in con- 
tractile dysfunction and muscle weakness [1,2]. 
The most severe form of GSDII is characterized by 
rapidly  progressing  cardiac  and  skeletal  myopathy, 
culminating in cardiorespiratory failure and death within 
the first 2 years of life [2–4]. There is a continuum of 
later onset disease that is accompanied by a spectrum of 
cardiac, skeletal, and smooth muscle myopathies, with a 
large number of patients succumbing to respiratory insuf- 
ficiency as a result of diaphragmatic weakness [5]. Early 
attempts to treat GSDII, including a high-protein diet, 
13-adrenergic drugs, thyroid and steroid hormones, and 
bone marrow transplantation, have largely been unsuc- 
cessful [6,7]. Currently, no effective treatment is widely 
available, although clinical trials have begun to evaluate 
weekly infusion of exogenously produced, purified recom- 
binant GAA [8–10]. 
FIG. 1. In vitro expression and 
lysosomal targeting of GAA in 
cells from GSDII patients. (A) 
Fibroblasts of GSDII patients were 
grown in 24-well plates and 
transduced with rAAV2-GAA or 
rAAV2-13gal in 2% fetal bovine 
serum/DMEM and harvested at 3, 
7, or 14 days  after  introduction 
of rAAV vectors. GAA activity was 
assayed   as   described.   rAAV2- 
13gal:100, control cells transduced rAAV2-13gal at an MOI of 100; rAAV2-GAA:10 and rAAV2-GAA:100, cells transduced with a rAAV2-GAA at an MOI of 10 and 
100, respectively. Bar graph represents mean ± SEM of GAA activities from independent triplicate cultures. (B) GSDII myoblasts were seeded in 24-well plates 
at a density of 2 x 104cells/cm2 and cultured to confluence in growth medium, then harvested at 3, 7, or 14 days after infection with rAAV2-GAA. GAA activi- 
ties were assayed as described. Untransduced, control cells with no rAAV vector; rAAV2-GAA, cells infected with rAAV2-GAA at an MOI of 10. Bar graph repre- 
sents mean ± SEM of GAA activities from independent triplicate cultures. (C) Fibroblasts from a GSDII patient incubated with an anti-GAA antibody and a 
FITC-conjugated secondary antibody (left) 8 days after infection with rAAV2-GAA. The same cells were also incubated with an anti-LAMP-1 antibody and a rho- 
damine-conjugated secondary antibody (middle). A digitally merged FITC/rhodamine image (right) shows co-localization of the two signals in yellow, confirm- 
ing that recombinant human GAA is sorted to the lysosomal compartment. Bar, 25 µm. 
In normal cells, the 110-kDa precursor form of GAA is 
core-glycosylated in the endoplasmic reticulum and 
acquires mannose 6-phosphate (M6P) residues in the cis 
Golgi. Most of the GAA precursor molecules are sorted 
from non-lysosomal enzymes and transported to the lyso- 
somal compartment via the M6P receptor. Successive 
cleavage of these precursors in the lysosome yields the 
95-, 76-, and 70-kDa forms of GAA, all of which are cat- 
alytically active [11]. The remaining glycosylated GAA pre- 
cursor molecules (about 10%) are not sorted to the lyso- 
somes; instead, they enter the secretory pathway. This 
circulating fraction can be recaptured by M6P receptors on 
the surface of cell membranes, internalized, and directed 
to lysosomes. Therefore GAA can reach the lysosome from 
both intracellularly derived protein and through a secre- 
tion-recapture pathway [12–14]. 
These observations are critical to the development of 
genetic therapies for GSDII because they provide a ration- 
ale for the delivery of recombinant GAA in trans after 
transduction of a repository of producer cells. Gene 
replacement strategies offer the potential for long-term 
expression of a therapeutic protein after a single adminis- 
tration of vector, and early studies using viral vectors as a 
delivery system for GAA have yielded promising results. 
Zaretsky et al. [15] demonstrated effective transduction of 
GAA-deficient myoblasts with a recombinant retrovirus 
vector. We and others [16–18] have constructed recombi- 
nant E1-deleted adenoviral vectors carrying the human 
GAA cDNA (rAd-GAA) and have demonstrated their abil- 
ity to direct expression of GAA both in vitro, in deficient 
fibroblasts, and in vivo after a single intramuscular or 
intracardiac injection [19]. Further investigation showed 
that deficient fibroblasts, after transduction with rAd-GAA 
in vitro, can serve as producer cells of recombinant GAA; 
that the recombinant protein can be secreted and recap- 
tured by untransduced acceptor cells; and that the M6P 
receptor mediates this recapture process [19]. When a sim- 
ilar virus carrying the mouse Gaa cDNA (rAd-Gaa) was 
administered intravenously to a GAA-deficient mouse 
(Gaa–/–) [20], secretion of the enzyme was demonstrated in 
vivo, with enzyme activity increased in both cardiac and 
skeletal muscle [19]. These results indicate that viral vec- 
tors have the potential to direct the synthesis of recombi- 
nant GAA in deficient cells. 
The early onset and robust expression from recombi- 
nant adenovirus vectors establishes important proof of 
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FIG. 2. Expression of recombinant human GAA in BALB/c mice after transduc- 
tion with rAAV2-GAA. Adult mice were treated with 1 x 109 i.u. of rAAV2-GAA 
in the tibialis anterior muscle, muscle tissues were isolated at the time points indi- 
cated, and assayed for GAA activity. The bar graph represents mean ± SEM GAA 
activity in five animals (weeks 1 and 4) or four animals (weeks 10 and 24). 
 
 
 
 
concept, however, adenovirus-mediated gene delivery elic- 
its host immune responses in immunocompetent subjects, 
leading to transient expression of the transgene in vivo 
[21]. We have also constructed recombinant adeno-asso- 
ciated viral (rAAV) vectors that express human and mouse 
GAA (rAAV-GAA and rAAV-Gaa, respectively). Adeno-asso- 
ciated virus (AAV) has gained widespread attention in 
recent years as a potential vector for recombinant gene 
transfer in humans [22,23]. AAV is a nonpathogenic 
human parvovirus containing single-stranded DNA that 
requires helper viruses, such as adenovirus or herpesvirus, 
or other factors in order to replicate [24]. Recombinant 
AAV vectors contain none of the wild-type viral genes and 
retain only the characteristic inverted terminal repeats 
(ITRs), the only cis-acting sequences required for recom- 
binant viral replication [25]. Neither recombinant nor 
wild-type AAVs cause any apparent disease in the host and 
lead to limited immunologic response. Early studies in our 
laboratory and others’ [26–30] demonstrated that intra- 
muscularly delivered rAAV is able to direct sustained 
expression of reporter and therapeutic genes. We report 
here the successful use of rAAV vectors to direct the syn- 
thesis of both human and murine GAA in vitro and in vivo, 
resulting in restoration of enzymatic activity and skeletal 
muscle contractility. 
 
RESULTS 
Human GAA Is Expressed and Is Enzymatically  
Active in GSDII Cells after in Vitro Transduction with 
rAAV2-GAA 
We first examined the expression of recombinant human 
GAA in deficient fibroblasts and myotubes from patients 
with GSDII. Deficient fibroblasts have no GAA activity, 
whereas deficient myotubes retain 50 to 80% of the GAA 
activity of normal human myotubes. At 14 days after 
rAAV2-GAA transduction, GAA activity in deficient fibro- 
blasts reached 30% of normal with a multiplicity of infec- 
tion (MOI) of 10, whereas GAA activities of 150% normal 
were observed at an MOI of 100 (Fig. 1A). In deficient 
myotubes transduced with rAAV2-GAA at an MOI of 10, 
a 10-fold increase (360.0 ± 122.9 versus 32.0 ± 5.3 
nmol/hour/mg) in enzymatic activity was observed 2 
weeks after transduction (Fig. 1B). These data indicate that 
rAAV2-GAA is capable of restoring GAA activity in defi- 
cient cells in vitro in a dose-dependent manner. 
To confirm that recombinant human GAA was being 
properly expressed and localized intracellularly, we probed 
for vector-derived human GAA protein in transduced, 
deficient cells. Immunofluorescent staining of human 
 
 
 
 
 
deficient fibroblasts transduced with rAAV2-GAA (Fig. 1C) 
showed that the protein is correctly targeted with a lyso- 
somal distribution pattern. To confirm the lysosomal tar- 
geting of GAA, we tested for co-localization of GAA and 
LAMP-1, a specific marker for mature lysosomes. Positive 
staining for GAA (green; Fig. 1C, left) was coincident with 
the LAMP-1 staining (red; Fig. 1C, middle), indicating that 
GAA protein expressed from rAAV2-GAA is indeed trans- 
ported to lysosomes (Fig. 1C, right). 
 
In Vivo Delivery of rAAV2 Vectors Results in Stable, 
Long-Term Expression of Human or Mouse GAA in 
Mouse Muscle 
To examine the efficiency and stability of rAAV2-medi- 
ated expression of GAA, we tested the vectors in vivo by 
injecting 1 x 109 i.u. of rAAV2-GAA into the tibialis ante- 
rior muscles of BALB/c mice. GAA expression was then 
assessed at 1 week, 4 weeks, 10 weeks, and 6 months after 
treatment (Fig. 2). We found that GAA enzymatic activity 
was increased over 150% in the tibialis anterior muscles 
at 1 week (168.1 ± 16.0 nmol/hour/mg treated versus 62.0 
± 3.1 control), and this level of activity was maintained or 
increased over 6 months, with the highest activities 
observed at the latest time point (397.9 ± 113.3 
nmol/hour/mg). The control group, which was injected 
with rAAV2-13gal, showed no change in GAA enzymatic 
activity over the same period. These data demonstrate that 
the rAAV2 is capable of expressing GAA efficiently, and 
that the expression is stable for up to 6 months after a sin- 
gle intramuscular injection. 
To provide further assurance that the observed enzy- 
matic activities were not due to increased basal production 
in the BALB/c strain, we treated GAA mutant mice (Gaa–/–) 
with rAAV2-Gaa. These mice have little or no residual GAA 
activity and have been shown to recapitulate many of the 
pathologic manifestations observed in human GSDII 
patients [20]. At 12 weeks after intramuscular delivery of 1 
x 109 i.u. of rAAV2-Gaa, we observed normal levels of GAA 
 
 
 
 
FIG. 3. rAAV2-Gaa-mediated transduction of skeletal and cardiac muscle in 
Gaa–/– mice. (A) Adult Gaa–/– mice were treated with 1 x 109 i.u. of rAAV2- 
Gaa in the quadriceps muscle. C57BL6/129SvJ controls and untreated Gaa–/– 
mice were sham-injected with sterile saline. Muscle tissues were isolated at 12 
weeks after treatment and assayed for GAA activity. The bar graph represents 
mean ± SEM GAA activity for five mice in each group. (B) After intubation and 
a left thoracotomy, 1 x 109 i.u. of rAAV2-Gaa were directly injected into the 
left ventricular free wall of Gaa-mutant mice. Untreated Gaa–/– mice were 
sham-injected with sterile saline. Muscle tissues were isolated 6 weeks after 
treatment, assayed for GAA activity, and compared with untreated age- 
matched C57BL6/129SvJ (wild-type) mice. The bar graph represents mean ± 
SEM GAA activity for four rAAV2-Gaa-treated mice and five mice in each of 
the control groups. 
 
 
 
To test the effect of restoration of GAA activity on con- 
tractile dysfunction in Gaa–/– mice, we injected 2 x 109 i.u. 
of rAAV2-Gaa directly into the soleus muscles of 6-week- 
olds. Isometric force generation was tested 6 weeks later, 
at 3 months of age (Fig. 4, filled triangles). At the maxi- 
mal stimulation frequency (200 Hz), treated Gaa–/– mice 
had intermediate contractile force (18.03 ± 2.05 N/cm2) rel- 
ative to untreated Gaa–/– and wild-type controls. Similar 
relationships in isometric tension were observed between 
wild-type, treated, and untreated Gaa–/– mice from 80 to 
150 Hz, indicating some amelioration of the muscle func- 
tion deficit over a range of physiologically relevant forces. 
 
 
 
 
 
 
 
 
 
 
enzyme activity in the mutant mice (32.6 ± 14.7 
nmol/hour/mg), as compared with C57BL6/129SvJ control 
mice (39.7 ± 1.0 nmol/hour/mg; Fig. 3A). Similar results 
were obtained after intramyocardial injections (1 x 109 i.u. 
rAAV2-Gaa) in Gaa–/– mice (Fig. 3B), demonstrating that 
recombinant mouse GAA expression can be directed by 
rAAV2-Gaa in both skeletal and cardiac muscle. 
 
Direct Intramuscular Delivery of rAAV2-Gaa Preserves 
Skeletal Muscle Contractile Force in Mutant Mice 
We tested the contractile properties of soleus muscles of 
mutant and wild-type hybrid mice using isometric force- 
frequency relationships as an index of contractile func- 
tion. Gaa–/– mice exhibited an age-dependent impairment 
of skeletal muscle function (Fig. 4, open squares), as evi- 
denced by their decreased maximal tetanic force (16.71 ± 
1.52 N/cm2) at higher stimulation frequencies compared 
with the matched control strain (20.86 ± 1.88 N/cm2; filled 
circles). This impairment is observed as early as 3 months 
of age (Fig. 4) and progressively worsens over the lifespan 
of the animal. 
Treatment of Gaa–/– Mice with rAAV1-Gaa Leads to 
Rapid Overexpression of Mouse GAA and Glycogen 
Clearance 
As rAAV2-mediated gene replacement led to wild-type lev- 
els of GAA enzymatic activity, we tested the ability of AAV 
serotype 1 (rAAV1) vectors to restore GAA activity as well. 
We injected 5 x 1010 total particles (as assessed by dot-blot 
analysis) of rAAV1-Gaa directly into the tibialis anterior (TA) 
muscles of 2-month-old Gaa–/– mice (n = 4), and the mice 
were sacrificed 2 weeks later. TA muscles were harvested, 
pooled, and homogenized. GAA activities (Fig. 5A) in treated 
Gaa–/– tissues (461.5 nmol/hour/mg protein) were nearly 
eight times wild type (65 nmol/hour/mg protein). Glycogen 
contents of TA muscles from untreated and treated Gaa–/– 
mice were 1.756 and 0.0219 µmol glucose/mg protein, 
respectively, compared with 0.128 µmol glucose/mg protein 
for wild-type mice. Proton nuclear magnetic resonance (1H- 
NMR) spectra of perchloric acid extracts from the same 
treated and untreated tissues showed a pronounced glyco- 
gen peak for Gaa–/– mice and complete amelioration of 
glycogen accumulation in rAAV1-Gaa treated mice. These 
findings indicate a reversal of glycogen accumulation after 
transduction with rAAV1-Gaa. 
 
DISCUSSION 
Pompe disease is due to a deficiency of GAA in all tissues, 
but is manifested primarily as cardiac and skeletal muscle 
weakness. Several mutant mouse models of GSDII have 
been developed [20,31], all of which mimic, according to 
one index or another, the myopathic phenotype associated 
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with GSDII. The Gaa–/– mouse used in these studies accu- 
mulates lysosomal glycogen and suffers from generalized 
skeletal myopathy, manifested in part by decreased loco- 
motor activity [20]. Our objective was to achieve sustained 
restoration of GAA activity from direct intramuscular 
delivery to cardiac or skeletal muscle. Additionally, we 
sought to test the ability of vector-derived GAA to restore 
contractile function in muscle. 
We constructed recombinant adeno-associated viruses 
that encode the full-length human GAA and mouse Gaa 
cDNAs and tested their ability to restore GAA activity in 
vitro in GAA-deficient fibroblasts and myotubes. Previous 
work had demonstrated the efficient transduction of these 
tissues with adenoviral vectors and indicated the utility of 
these cells as an in vitro system to evaluate potential ther- 
apies [15–18].  In  this report, high-level  expression  of 
recombinant human GAA was achieved in both GAA-defi- 
cient fibroblasts and myotubes transduced in vitro with 
rAAV2-GAA, demonstrating that the human GAA cDNA is 
capable of directing synthesis of functional GAA protein 
in the context of rAAV. 
 
 
 
FIG. 4. Force-frequency relationships of intact soleus muscles after direct intra- 
muscular delivery of rAAV2-Gaa. 2 x 109 i.u. of rAAV2-Gaa were directly deliv- 
ered to the soleus muscles of 2-month-old Gaa–/– mice (n = 3). Muscles were 
isolated 6 weeks after treatment, tested for isometric force generation, and 
compared with untreated C57BL6/129SvJ (wild-type) (n = 6) and Gaa–/– mice 
(n = 5), respectively. 
 
 
 
In vivo experiments confirmed that rAAV2-GAA and 
rAAV2-Gaa were able to direct long-term enzymatic activ- 
ity in treated mice.  Stable expression of recombinant 
human GAA was observed for up to 6 months after a sin- 
gle intramuscular injection of rAAV2-GAA. In treated 
Gaa–/– animals, near-normal levels of mouse GAA activity 
were observed in skeletal muscle 12 weeks after adminis- 
tration of 109 i.u. (~ 1013 genomes/kg); concomitant 
improvement of muscle contractile function was observed 
in the higher frequency (that is, clinically relevant) stim- 
ulation range. These results are consistent with previous 
observations of efficient skeletal muscle transduction with 
rAAV vectors, as demonstrated with reporter [26–30] and 
therapeutic genes [26,28,32–34], as well as with genes 
encoding muscle contractile apparatus proteins [35,36] 
and that mutated in another lysosomal storage disease, 
mucopolysaccharidosis VII [37]. Likewise, intramuscular 
treatment with rAAV1-Gaa led to nearly eight times wild- 
type levels of GAA activity, demonstrating highly effective 
gene transfer in skeletal muscle with rAAV1, as has been 
observed previously in other models [38–40]. 
Our data  indicate that rAAV2-Gaa  delivery to the 
myocardium of Gaa–/– mice effectively restores GAA enzy- 
matic activity, and is among the first examples of rAAV- 
mediated delivery of a therapeutic gene to the 
myocardium. In a previous report, Svensson et al. [41] 
described both direct intramyocardial delivery and intra- 
coronary perfusion as potential methods for efficient rAAV 
delivery to the myocardium using 13-galactosidase as a 
reporter. Recently, direct delivery of rAAV encoding 
recombinant vascular endothelial growth factor (rVEGF) 
 
 
 
FIG. 5. rAAV1-Gaa-mediated transduction of skeletal muscle in Gaa–/– mice. (A) 5 x 1010 particles of rAAV1-Gaa were directly delivered to the tibialis anterior 
muscles of  2-month-old  Gaa–/– mice  (n =  4).  Muscles  were  harvested,  pooled,  and  homogenized  2  weeks after  treatment  and  compared  with  untreated 
C57BL6/129SvJ (wild-type) and Gaa–/– mice, respectively. (B) In vitro glycogen content determination for the same muscle homogenates. (C) Stacked 1H-NMR 
spectra from the same homogenates after perchloric acid extraction. Glycogen peaks are observed at 5.4 ppm. 
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has been used to induce neovascularization in an ischemic 
mouse model [42]. Likewise, Kawada et al. have demon- 
strated restoration of cardiac function in dystrophic mice 
[43] after direct intramural delivery of rAAV expressing 
o-sarcoglycan. The present work represents the first 
attempt to use adeno-associated virus vectors to address a 
metabolic cardiomyopathy, and investigations with regard 
to cardiac function after rAAV-mediated GAA restoration 
are ongoing. 
The clinical heterogeneity of GSDII suggests that poten- 
tial therapies must address the primary enzymatic defi- 
ciency in both skeletal and cardiac muscle. Numerous 
reports have indicated that circulating recombinant GAA, 
either purified protein or viral vector-derived, might serve 
as an effective method of delivery of GAA to muscle 
tissue. Several groups, including our own, have sought to 
take advantage of cell surface mannose 6-phosphate recep- 
tors to mediate the transport of circulating enzyme to the 
lysosomal compartments of individual cells. Studies with 
intravenous delivery of recombinant human GAA protein 
have indicated that this strategy may be beneficial in Gaa–/– 
mice and human subjects [8–10]. Our ongoing investiga- 
tion will determine whether clinically relevant circulating 
enzyme concentrations can be sustained, particularly 
given the potential for neutralizing antibody responses to 
intravenously administered recombinant enzyme replace- 
ment therapy [44]. 
Data from Gaa–/– transgenic mice that express human 
GAA in a conditional, muscle-specific manner [45] indicate 
that several-fold overexpression of human GAA was 
required in order to achieve systemic restoration of GAA 
activity in non-muscle tissues. Given these data, the near- 
normal enzymatic activity observed after intramuscular 
delivery of rAAV2-Gaa (Fig. 3A) is not likely to provide 
sufficient circulating concentrations of GAA for systemic 
correction; in fact, no change in enzymatic activity was 
observed in the liver, heart, or uninjected (distal) skeletal 
muscles with the enzymatic activities reported here (data 
not shown). By contrast, GAA activities after intramuscu- 
lar delivery of rAAV1-Gaa resulted in nearly eight times 
wild-type enzyme activity levels (Fig. 5), with concomitant 
clearance of glycogen from the injected tissue. Due to the 
relative size of the tibialis anterior muscle, we did not seek, 
in this report, to substantially increase circulating con- 
centrations of recombinant GAA secreted from muscle. 
However, these data suggest that a larger, well-perfused 
muscle may be capable of serving as a production site for 
systemic therapy for GSDII. Further studies are underway 
to address this question. 
We should note that the metrics used to analyze 
phenotypic correction of GSDII in both mice and humans 
are an area of active development in our laboratory and 
others. One potentially clinically important outcome is 
the co-localization of both active GAA enzyme and the 
clearance of lysosomal glycogen. So far, clinical trials with 
both intravenously delivered CHO- and transgenic rabbit 
milk-derived human GAA have led to variable increases in 
GAA enzymatic activity in skeletal and cardiac muscle, 
with achieved developmental milestones and reductions 
in cardiac mass. However, despite these promising obser- 
vations, reductions in total tissue glycogen content have 
been reported in only one patient among the seven 
patients studied in two separate trials. We have recently 
begun to use magnetic resonance imaging and spec- 
troscopy techniques in an effort to better understand the 
dynamics of glycogen clearance in vector-treated Gaa–/– 
mice (Fig. 5). The initial observations suggest that this 
technique will be very useful in longitudinal studies of 
treated mice. In addition to glycogen content, important 
morphological characteristics of skeletal muscle will also 
be evaluated in future studies. 
We have described the use of recombinant adeno-asso- 
ciated virus vectors to correct the primary enzymatic defect 
in GSDII. These data suggest that adeno-associated virus- 
mediated gene transfer represents a feasible and poten- 
tially powerful strategy for the delivery of gene products 
to specific myopathic tissue. Given the short half-life of 
GAA in vivo (2–4 days [46]), gene therapy vectors with 
capabilities for both high-level and long-term persistent 
transgene expression will be required. We anticipate that 
direct delivery of rAAV will have broad applicability for the 
delivery of a variety of recombinant gene products to the 
failing heart and for the treatment of many inherited 
forms of skeletal and cardiac myopathy. 
 
MATERIALS AND METHODS 
Molecular cloning of rAAV vectors carrying the human GAA and mouse 
Gaa genes. The human GAA and mouse Gaa cDNAs were constructed as 
described [19]. The full-length cDNAs were placed under the transcrip- 
tional control of the cytomegalovirus (CMV) immediate early promoter in 
the mammalian expression plasmid pCI (Clontech, Palo Alto, CA), yield- 
ing pCI-GAA and pCI-Gaa. The expression cassettes were then cloned into 
p43.2, a plasmid containing both of the AAV serotype 2 inverted terminal 
repeats (ITRs). The human vector plasmid, p43.2-GAA, was generated via 
EcoRI–XbaI, and p43.2-Gaa was similarly cloned via SpeI-MunI. A control 
recombinant AAV vector plasmid (pAAV-13gal) carrying the gene encoding 
Escherichia coli 13-galactosidase under the transcriptional control of the CMV 
promoter has been described [26]. 
To confirm the enzymatic activity of recombinant GAA produced from 
p43.2-GAA and p43.2-Gaa, rAAV vector plasmids were transfected into 
COS-1 cells, and GAA activity was measured 72 h after transfection, as 
described below. An 8- to 10-fold increase in activity was observed after 
transfection with p43.2-GAA or p43.2-Gaa, compared with untransfected 
cells or cells transfected with pAAV-13gal (data not shown). The Johns 
Hopkins University DNA Analysis Facility confirmed DNA sequences for the 
two rAAV  GAA plasmids  using an  automated sequencing  protocol. 
Infectious rAAV2-GAA, rAAV2-Gaa, and rAAV2-13gal vectors were packaged 
and titered as described [47–49]. The current packaging protocol yields 
AAV particles that have a ratio of DNA-containing to infectious particles 
of < 100. SDS/PAGE and silver stain, infectious center assay, particle count, 
and electron microscopy were used to fully characterize high-titer vector 
stocks (up to 1 x 1011 infectious units (i.u.)/mL). Similar techniques were 
used to produce and isolate rAAV1-Gaa vectors. 
Cell lines and in vitro and in vivo viral transduction. Cultured cells were 
maintained in 5% CO2 at 37°C. GAA-deficient fibroblasts isolated from an 
infant with GSDII (GM04912) were obtained from the NIGMS Mutant Cell 
 
 
 
 
Repository (Camden, NJ). Normal human skeletal muscle cells were 
obtained from Clonetics Corporation (Walkersville, MD). 
LGM04912 cells were cultured in 24-well plates at a density of 1 x 105 
in growth medium (GM; 20% [vol/vol] fetal calf serum (FCS) in DMEM). 
In vitro transduction with rAAV was performed in Opti-MEM and, after 
viral adsorption, cells were cultured in 2% FCS in DMEM. Normal and 
deficient human myoblasts were seeded in 24-well plates at a density of 
Cells were incubated with tetramethyl rhodamine-conjugated goat anti- 
mouse IgG and fluorescein-conjugated goat anti-rabbit IgG. 
Perchloric acid extraction and 1H-NMR spectroscopy.  Mice were fasted 
overnight to lower background glycogen to minimal levels. Upon sacrifice, 
samples were prepared by rapid freezing in liquid nitrogen and pulveriza- 
tion into a fine powder. Liquid nitrogen was evaporated and the powder 
was transferred to a 15 mL polypropylene tube containing 3 mL 7% 
2 x 104cells/cm2 and cultured to confluence in GM. Once the cells reached (vol/vol) perchloric acid in 50 mM NaH2PO4. The  sample  was  vortexed 
confluence, differentiation medium (DM; 2% [vol/vol] horse serum in 
DMEM) was substituted to induce myoblast fusion and myotube formation. 
After 14 days of incubation in DM, myotubes were transduced with 
purified rAAV vectors in Opti-MEM. DM was reintroduced after viral 
adsorption. All media and sera were purchased from Life Technologies 
(Gaithersburg, MD). 
All animal procedures were performed in accordance with the guide- 
lines of the Animal Care and Use Committees of the Johns Hopkins 
University and the University of Florida College of Medicine. Delivery of 
recombinant viral vectors to mouse skeletal muscle has been described 
[26]. BALB/c mice were anesthetized with inhaled methoxyflurane, and 
1 x 109 i.u. of rAAV2-GAA or rAAV2-13gal were injected into the tibialis ante- 
rior muscle after minimal exposure of the muscle via a single incision. For 
intramuscular rAAV2-Gaa experiments, rAAV2-Gaa (1 x 109 i.u.) was 
injected into the quadriceps muscle of Gaa–/– mice [20] using minimal 
exposure; mice were then sutured as described before. Control mice of the 
same genetic background (C57BL6/129SvJ) were injected with identical 
volumes of sterile saline. 
To facilitate direct injection into cardiac muscle, adult Gaa–/– and con- 
trol mice were anesthetized with an intraperitoneal (IP) injection of a ket- 
amine/xylazine (100 mg/kg ketamine; 15 mg/kg xylazine) cocktail. Animals 
were placed in a supine position in a sterile surgical field. The trachea was 
exposed and a 22G catheter was introduced to facilitate ventilation using 
an SAR-830AP rodent ventilator (CWE, Ardmore, PA). The animal was ven- 
tilated at 110 breaths/min with a tidal volume of 0.2 cc/min. A left thora- 
cotomy was performed, and the ribs were retracted to give full visualiza- 
tion of the left ventricle. Injections of 10 to 50 µL were carried out with a 
29-gauge insulin syringe. The ribs and skin were closed, and the animal was 
weaned from the ventilator. All animals were monitored overnight for pain 
or distress and for 1 week or more for infection or other complications. 
Assays of GAA activity and glycogen concentration. Enzymatic activity 
assays for GAA were performed as described [16]. Transduced tissue culture 
cells were harvested and lysed in a commercial lysis buffer (Analytic 
Luminescence Lab). Alternatively, harvested muscle tissues were homoge- 
nized in water, then subjected to three freeze-thaw cycles. Lysates were cen- 
trifuged and clarified supernatants were assayed for GAA activity by meas- 
repeatedly and centrifuged at 4°C and 4000 rpm for 15 minutes. The super- 
natant was transferred to a new tube and neutralized to pH 7.0 with 5 M 
potassium hydroxide, leading to precipitate formation. The precipitate was 
removed by centrifugation; the supernatant was transferred to a new tube, 
and paramagnetic metals and excess salts were removed by incubation 
with pre-washed Chelex beads at a 1:8 ratio for 20 minutes at 4°C. The mix- 
ture was filtered through a 0.22 µm filter and lyophilized overnight. 
Samples were resuspended in D2O for spectroscopy. 
Proton nuclear magnetic resonance (1H-NMR) measurements were per- 
formed using a Bruker Avance 500 spectrometer with an 11.75 T Magnex. 
Spectra were collected under unsaturated conditions at 258C and pH 7.0 (TR 
= 5 seconds, sweep width = 6.666 KHz, pulse width = 5.5 µsec, number of 
averages = 256, number of points = 40K). Integrated areas and chemical shifts 
were referenced to the total creatine peak (3.0 ppm) for each sample. 
Assessment of skeletal muscle function. Direct intramuscular injections 
of rAAV2-Gaa (2 x 109 i.u.) or lactated Ringer’s were performed in the 
soleus muscle of Gaa–/– mice. After 6 weeks, the mechanical function of the 
muscles was assessed. Gaa–/– and C57BL6/129SvJ controls were anesthetized 
via IP injection of ketamine/xylazine. After reaching a surgical plane of 
anesthesia, the soleus muscles are surgically excised and placed in a cooled 
dissecting chamber containing Krebs-Henseleit solution, equilibrated with 
a 95% O2/5% CO2 gas mixture. The intact muscles are then vertically sus- 
pended between two lightweight Plexiglas clamps connected to force trans- 
ducers (Model FT03, Grass Instruments, West Warwick, RI) in a water-jack- 
eted tissue bath containing Krebs-Henseleit solution equilibrated with a 
95% O2 /5% CO2 gas (bath ~ 37 ± 0.5°C, pH ~ 7.4 ± 0.05, osmolality ~ 290 
mOsmol). Transducer outputs are amplified and differentiated by opera- 
tional amplifiers and undergo A/D conversion for analysis using a computer 
based data acquisition system (Polyview, Grass Instruments). 
In vitro contractile measurements begin with empirical determination 
of the muscle’s optimal length (Lo) for isometric tetanic tension develop- 
ment. The muscle is field-stimulated using a stimulator (Model S48, Grass 
Instruments) along its entire length with platinum electrodes. Muscle 
length is progressively increased until maximal isometric twitch tension is 
obtained. Once the highest twitch force is achieved, all contractile prop- 
erties are measured isometrically at Lo. The force-frequency relationship was 
uring     the     cleavage     of     the     synthetic     substrate     4-methyl- 
umbelliferyl-a.-D-glucoside (Sigma M9766, Sigma-Aldrich, St. Louis, MO) after 
incubation for 1 hour at 37°C. Successful cleavage yielded a fluorescent prod- 
uct that emits at 448 nm, as measured with a TKO100 fluorometer. Protein 
concentration was measured using a standard bicinchoninic acid method (Bio-
Rad, Hercules, CA), with bovine serum albumin as a standard. Data are 
represented as nanomoles of substrate cleaved in 1 hour per milligram of total 
protein in the lysate (nmol/hour/mg). Glycogen concentration was assessed 
by measuring the amount of glucose released from tissue homogenates after 
treatment with amyloglucosidase as described [18,50]. 
Immunocytochemistry. For immunofluorescence microscopy, cells on cov- 
erslips were fixed with 50% methanol/50% acetone (vol/vol) at –20°C for 
15 minutes. Samples were blocked with 50% FBS/50% PBS (vol/vol) for 1 
hour at room temperature, then incubated for 1 hour at 25°C with a pre- 
viously described rabbit-derived anti-human GAA antiserum [16], diluted 
1:1000 in phosphate-buffered saline (PBS) with 50% FCS and 0.01% NaN3. 
Cells were washed in PBS three times and incubated for 1 hour at 25°C with 
fluorescein isothiocyanate-conjugated goat anti-rabbit antibody. The slips 
were again washed three times, mounted with an aqueous/dry-mounting 
medium (Biomeda, Foster City, CA), and examined with fluorescence 
microscopy. For localization of human GAA in the lysosomal compart- 
ment, transduced cells were fixed and probed simultaneously with a mouse 
monoclonal antibody recognizing human lysosome-associated membrane 
protein-1 (LAMP-1) and rabbit anti-human acid a.-glucosidase antiserum. 
examined as described [51,52]. 
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